Patents by Inventor Pradeep Dhal
Pradeep Dhal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240207033Abstract: A method of manufacturing a therapeutic device includes providing a member that defines first pores having a first average size that (i) allows passage of a therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The method further includes spinning the member about an axis of the member and applying a fibrous material to the member while the member spins to form a coating that surrounds the member. The coating defines second pores having a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the coating. The member and the coating together form a container of the therapeutic device, and the container defines an interior region for accommodating a plurality of cells capable of producing the therapeutic agent.Type: ApplicationFiled: April 25, 2022Publication date: June 27, 2024Inventors: Lionel Vedrine, Christina Laskar, Pradeep Dhal, Craig Harvey Nelson, Mark Robson Humphries, Carys Eleri Lee, Nicholas Oliver Harding
-
Publication number: 20240207588Abstract: A method of manufacturing a therapeutic device includes forming a container wall that is sized to contain multiple cells capable of producing a therapeutic agent within an interior region of the container wall. The method further includes exposing the container wall to a solvent to remove material from the container wall to define first pores along an interior portion of the container wall and second pores along an exterior portion of the container wall. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior portion.Type: ApplicationFiled: April 25, 2022Publication date: June 27, 2024Inventors: Lionel Vedrine, Christina Laskar, Pradeep Dhal, Craig Harvey Nelson, Mark Robson Humphries, Carys Eleri Lee, Nicholas Oliver Harding
-
Publication number: 20240197959Abstract: An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container and a substance capable of reacting to generate oxygen for the multiple cells within the interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior wall portion.Type: ApplicationFiled: April 25, 2022Publication date: June 20, 2024Inventors: Lionel Vedrine, Christina Laskar, Pradeep Dhal, Craig Harvey Nelson, Mark Robson Humphries, Carys Eleri Lee, Nicholas Oliver Harding
-
Publication number: 20240197464Abstract: An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent and oxygen through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization and oxygen transfer along the exterior wall portion.Type: ApplicationFiled: April 25, 2022Publication date: June 20, 2024Inventors: Lionel Vedrine, Christina Laskar, Pradeep Dhal, Craig Harvey Nelson, Mark Robson Humphries, Carys Eleri Lee, Nicholas Oliver Harding
-
Publication number: 20240182595Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: September 7, 2023Publication date: June 6, 2024Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Patent number: 11807690Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: October 17, 2019Date of Patent: November 7, 2023Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
-
Publication number: 20220089763Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: August 17, 2021Publication date: March 24, 2022Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 11130816Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 3, 2019Date of Patent: September 28, 2021Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20210017237Abstract: This disclosure relates to antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV. Also disclosed are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SanofiInventors: Gary J. Nabel, Chih-Jen Wei, Kurt Swanson, Pradeep Dhal, Ram Dharanipragada, Magnus Besev
-
Patent number: 10806797Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.Type: GrantFiled: June 2, 2016Date of Patent: October 20, 2020Assignee: SANOFIInventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Pradeep Dhal, Paul Konowicz, Robert Miller, James Stefano, Magnus Besev, Martin Bossart, Katrin Lorenz, Torsten Haack, Andreas Evers
-
Publication number: 20200140564Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: October 17, 2019Publication date: May 7, 2020Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Publication number: 20200023070Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon/GIP triple receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y-R2 groups, wherein Y represents an GLP-1/Glucagon/GIP triple receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon/GIP triple receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon/GIP triple receptor agonist.Type: ApplicationFiled: May 30, 2019Publication date: January 23, 2020Inventors: Dieter Kadereit, Thomas Olpp, Michael Walden, Nils Poth, Mandy Mohnicke, Michael Wagner, Pradeep Dhal
-
Patent number: 10494439Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: June 5, 2017Date of Patent: December 3, 2019Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
-
Publication number: 20190233531Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 3, 2019Publication date: August 1, 2019Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 10214589Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 27, 2017Date of Patent: February 26, 2019Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 10113032Abstract: Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.Type: GrantFiled: March 24, 2016Date of Patent: October 30, 2018Assignee: Genzyme CorporationInventors: Pradeep Dhal, Kanwen Yang, Robert J. Miller, Stephen Randall Holmes-Farley
-
Publication number: 20180289822Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.Type: ApplicationFiled: June 2, 2016Publication date: October 11, 2018Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Pradeep DHAL, Paul KONOWICZ, Robert MILLER, James STEFANO, Magnus BESEV, Martin BOSSART, Katrin LORENZ, Torsten HAACK, Andreas EVERS
-
Publication number: 20170369584Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: June 5, 2017Publication date: December 28, 2017Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Publication number: 20170267774Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 27, 2017Publication date: September 21, 2017Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 9701753Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: March 10, 2014Date of Patent: July 11, 2017Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio